Author:
Ashizawa Tadashi,Iizuka Akira,Maeda Chie,Tanaka Emiko,Kondou Ryota,Miyata Haruo,Sugino Takashi,Kawata Takuya,Deguchi Shoichi,Mitsuya Koichi,Hayashi Nakamasa,Asai Akira,Ito Mamoru,Yamaguchi Ken,Akiyama Yasuto
Funder
Shizuoka Prefectural Government, Japan
Subject
Immunology,Immunology and Allergy
Reference39 articles.
1. Pancreatic cancer;Kamisawa;Lancet,2016
2. ESMO Guidelines Working Group, Pancreatic adenocarcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up;Seufferlein;Ann. Oncol. Suppl,2012
3. A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma;Jamieson;Ann. Surg. Oncol.,2011
4. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomized, non-inferiority trial (JASPAC 01);Uesaka;Lancer,2016
5. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine;Von Hoff;N. Engl. J. Med.,2013
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献